This Continuing Education activity is supported by an educational grant from Amgen.
Joel C. Marrs, PharmD, FASHP, FCCP, FNLA, BCPS-AQ Cardiology, BCACP, CLS, ASH-CHC
Advertisement
Articles by Joel C. Marrs, PharmD, FASHP, FCCP, FNLA, BCPS-AQ Cardiology, BCACP, CLS, ASH-CHC
Advertisement
Latest Updated Articles
The Impact of PCSK9 Inhibition in Dyslipidemia ManagementPublished: April 24th 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
2
Recognizing Immunizing Pharmacists in the Community
3
FDA, HHS Move to Accelerate Biosimilar Approvals
4
Accelerated Approval of Cancer Drugs: Benefit or Burden?
5
